Skip to main content
Hit enter to search or ESC to close
Close Search
AdvanCell
  • Contact
Menu
  • Home
  • Company
  • Partners and Investors
  • News
  • Contact
    NewsPresentations/Publications

    Alpha-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer

    7 October 20251 min read

    Anna Karmann, Shahneen Sandhu, Louise Emmett, Oliver Sartor, Clemens Kratochwil, Stephen Rose, Ken Herrmann​

    ​

    Read the full article here: α-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer | Journal of Nuclear Medicine​

    ​

    Also read our recent pre-clinical paper: Preclinical Evaluation of [212Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen–Targeted α-Therapy for Prostate Cancer | Journal of Nuclear Medicine​

    AdvanCell is a radiopharmaceutical company that is developing a revolutionary cancer treatment called Targeted Alpha Therapy, providing new hope for patients with untreatable cancers.

    Quick Links

    • Home
    • Company
    • Partners and Investors
    • News
    • Contact

    Locations

    Sydney
    Brisbane
    Translational Research Institute
    Brisbane
    Richlands
    Adelaide
    Boston

    Contact Us

    contact@advancell.com.au

    Copyright © 2026 AdvanCell Pty Ltd. All Rights Reserved. Website by

    Privacy Policy • Terms of Service • Cookie Policy • Acceptable Use Policy

    Share
    Share Share Share Pin
    Close Menu
    • Home
    • Company
    • Partners and Investors
    • News
    • Contact

    Locations

    Sydney
    Brisbane
    Translational Research Institute
    Brisbane
    Richlands
    Adelaide
    Boston
    • linkedin